Closed · RFA-FD-14-019 · CFDA 93.103 · Discretionary
Evalution of Iron Species in Healthy Subjects treated with Generic and Reference Sodium Ferric Gluconate
Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.
- $450K-$500K
- Award range
- Closed
- Status
- June 19, 2014
- Close date
- 1
- Expected awards
The verdict
Evalution of Iron Species in Healthy Subjects treated with Generic and Reference Sodium Ferric Gluconate is a closed discretionary listing from Food and Drug Administration that offered $450,000 -- $500,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.
- $450K-$500K
- award range
- Closed
- application status
- 1
- expected award
- 93.103
- CFDA program
Archived opportunity record
Evalution of Iron Species in Healthy Subjects… is closed (last close June 19, 2014). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed June 19, 2014
Est. Total Funding
$15,000,000
Expected Awards
1
Instrument
Cooperative Agreement
Description
Parenteral iron injection products are used to treat anemia, particularly in patients with chronic kidney disease (CKD). There are a number of parenteral iron complex products available in North America: iron sucrose, sodium ferric gluconate, iron dextran, ferumoxytol, and others. All parenteral iron products are colloids comprising a continuous aqueous medium and particles of carbohydrate protected iron oxyhydroxide. After intravenous administration, iron colloid particles are processed by phagocytes and iron ions are delivered to the lysosomes within the cell as part of the intracellular labile iron pool. The phagocyte uptake and biodistribution of iron complex particles depend upon their physicochemical properties. If iron is not needed immediately, it is stored in the form of ferritin or hemosiderin. When the iron is needed in the body, iron is released from the cell and transferrin binds iron ions and delivers them to their destination. If transferrin is oversaturated or if the iron complex product is so unstable that iron is spontaneously released at a rate that exceeds transferrin binding capacity, non-transferrin bound iron (NTBI) is formed in the plasma. NTBI can be toxic to cells as it acts as a catalyst in the formation of free radicals from reactive oxygen species. In March 2011, FDA approved the first generic sodium ferric gluconate iron complex Nulecit™, an alternative to Ferrlecit®. FDA's approval of generic iron complex products was based on equivalence in formulation composition (qualitatively and quantitatively the same), product physicochemical characteristics, as well as equivalence in in vivo pharmacokinetic. Products that meet these approval standards should have no significant difference in NTBI. Since 2008 there are multiple reports about the safety and efficacy of generic iron colloid products on the European and Asian markets. These products have caused public concerns and have been cited in several citizen petitions that question FDA’s equivalence recommendations for iron sucrose and sodium ferric gluconate complex in sucrose injection. On March 17, 2011, the European Medicines Agency published the Reflection Paper on Non-Clinical Studies for Generic Nanoparticle Iron Medicinal Product Applications. This paper suggested that generic iron formulations could have higher levels of labile iron, leading to the formation of a greater amount of nontransferrin-bound iron in vivo than the RLD that would potentiate oxidative stress and inflammation and result in direct cellular damage and possibly increasing the risk of atherosclerotic disease. This paper concluded that “Comparative data from non-clinical studies on the time-dependent iron content in the major target organs may be used to support the claim of essential similarity of generic and reference nanoparticle iron medicinal products”. To confirm the agency’s approval criteria and bridge the gap between equivalence standards from FDA and EMA, well controlled and prospective studies that compare NTBI levels between brand and generic in healthy subjects may be needed. Objective: The objective of this study is to conduct in vivo studies to compare plasma total iron (TI), transferrin bound iron (TBI), non-transferrin bound iron (NTBI) levels and oxidative stress after i.v. administration of RLD and generic sodium ferric gluconate injections in healthy subjects. This study is part of post-market surveillance on approved generic products, which can help address potential concerns regarding the quality of generic iron complex products and support the Agency’s review standards. Detailed Descriptions: A prospective, randomized, 2-way crossover study to compare plasma TI, TBI, NTBI levels in healthy subjects treated with generic and reference sodium ferric gluconate injections is preferred. Utilize in vitro and in vivo biomarkers such as malondialdehyde, heme-oxygenase-1 (HO-1) RNA or others to evaluate the oxidative stress and toxicity caused by generic and RLD products. 1. Collect marketed brand and generic sodium ferric gluconate products and compare them in terms of potency, impurity, and other drug product quality attributes. 2. Develop bio-analytical methods to determine plasma TI, TBI, and NTBI concentrations. 3. Conduct a prospective, randomized, 2-way crossover study to compare plasma TI, TBI, NTBI levels in healthy subjects treated with generic and RLD. Monitor TBI, total iron binding capacity and serum ferritin level during washout period to ensure iron storage and transport has returned to baseline. 4. Evaluate the oxidative stress and toxicity caused by generic and RLD using in vitro and in vivo biomarkers. 5. Monitor any side effects or adverse reactions during the study period. 6. Conduct statistical analysis to determine whether there are any significant differences between generic and RLD in NTBI level and others.
Wide-open applicant board · 15 Grants.gov doors
Evalution of Iron Species in Healthy Subjects… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). 120 other Food and Drug Administration listings share this eligibility-code string (25% of 482).
- Code 00
- State governments
- Code 01
- County governments
- Code 02
- City or township governments
- Code 04
- Special district governments
- Code 05
- Independent school districts
- Code 06
- Public / state-controlled institutions of higher education
- Code 07
- Federally recognized tribal governments
- Code 08
- Public / Indian housing authorities
- Code 11
- Native American tribal organizations (other than Federally recognized tribal governments)
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Food and Drug Administration Research
U.S. Department of Health and Human Services
Agency Contact
Gladys Melendez-Bohler Grants Management Officer/Specialist Phone 240-402-7565
More from Food and Drug Administration
Federal and University Partnership to Improve the Safety of Seafood from the Gulf of America
Research, Education, and Outreach on Botanical Natural Products
Cooperative Agreement to Support Shellfish Safety Assistance Project
Education and Outreach to Tribal Producers through the Tribal Food Safety Alliance
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional
What to do next
Evalution of Iron Species in Healthy Subjects… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
- Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
- Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |